ProCE Banner Activity


Personalizing Myelofibrosis Care: Expert Insights on New Evidence and Novel Strategies


On-demand webcast of expert faculty presentation on personalizing myelofibrosis care, including review of current guidelines and recommendations, available therapies for treatment, and what’s on the horizon.

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

Released: April 24, 2024

Expiration: April 23, 2025



Pankit Vachhani

Pankit Vachhani, MD

Associate Professor of Medicine, UAB Division of Hematology/Oncology
Medical Director, Clinical Research Unit (CRU) at UAB
O’Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc. and Incyte Corporation.

AbbVie Inc.

Incyte Corporation

Target Audience

This activity has been designed to meet the educational needs of hematologists/oncologists, pharmacists, physician associates, nurse practitioners, nurses, and other HCPs involved in managing patients with myelofibrosis.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Describe factors that contribute to cancer health disparities and their potential impact on outcomes for patients with myelofibrosis

  • Integrate available therapies into an optimal first-line treatment strategy for patients with myelofibrosis, considering risk stratification, molecular features, cytogenetics, and symptom burden

  • Design evidence-based second-line treatment approaches for patients with myelofibrosis who are relapsed, refractory, or intolerant to prior JAKi therapy

  • Evaluate the toxicity profiles of current and emerging therapies to develop AE management plans that support patients’ QoL and treatment continuity

  • Summarize new data on emerging agents to facilitate discussions about ongoing trial opportunities with eligible patients


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Pankit Vachhani, MD

Associate Professor of Medicine, UAB Division of Hematology/Oncology
Medical Director, Clinical Research Unit (CRU) at UAB
O’Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama

Pankit Vachhani, MD: consultant/advisor/speaker: AbbVie, Amgen, Blueprint Medicines, Cogent, CTI BioPharma Corp (now Sobi), Daiichi Sankyo, Genentech, GlaxoSmithKline, Incyte, Karyopharm, LAVA Therapeutics, Merck, MorphoSys, Novartis, Pfizer, Servier, Stemline.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except ​Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.​

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, CTI/SOBI, Daichii Sankyo, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 24, 2024, through April 23, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-108-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until April 23, 2025. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

Successful completion of this CME activity, which included participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).